Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY ups shipments to GNC

This article was originally published in The Tan Sheet

Executive Summary

NBTY is in the process of "dropping more new products into GNC" stores as the firm completes changes to the recently acquired Rexall MET-Rx sports nutrition brand product mix and labeling, Chairman & CEO Scott Rudolph says in Jan. 22 earnings call (1"The Tan Sheet" Nov. 17, 2003, p. 10). CFO Harvey Kamil adds that NBTY plans to double the run rate of its fast-selling low carb offerings - CarbWise and CarbSolutions - over the next 12 months. The vertically integrated supplement manufacturer reports a 60% increase in revenue to $385.1 mil. and a net income rise of 24% to $23.6 mil. in the first quarter ended Dec. 31. US Nutrition wholesale division leads NBTY business units with 142% sales growth to $179.2 mil., in part due to strong sales from Nature's Bounty, Osteo-Bi-Flex and Sundown brands...

You may also be interested in...



NBTY Shopping Has A Price As Charges Contribute To Earnings Drop

NBTY net earnings fell 46% to $15.9 mil. in the fourth quarter, pulled down by a $4 mil. charge relating to the aborted acquisition of Twinlab, the company said Nov. 10

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered. 

OIG: FDA’s EUA Approach Allowed Bad Tests To Reach Market

A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS096405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel